Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive
Suite 101
San Diego, CA 92121
United States
858 752 6170
https://www.cidara.com
版塊: Healthcare
行業: Biotechnology
全職員工: 69
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Jeffrey L. Stein Ph.D. | President, CEO & Executive Director | 836.56k | 無 | 1955 |
| Mr. Shane M. Ward | Chief Legal Officer,Corporate Secretary & COO | 579.88k | 無 | 1975 |
| Dr. Taylor Sandison M.D., M.P.H. | Chief Medical Officer | 620.65k | 無 | 1972 |
| Dr. Kevin M. Forrest Ph.D. | Founder and Chief Strategy Officer | 311.27k | 無 | 1977 |
| Dr. Preetam Shah M.B.A., Ph.D. | CFO, Chief Business Officer & Principal Accounting Officer | 539.64k | 無 | 1973 |
| Ms. Allison Lewis CCP, SPHR | Senior Vice President of People & Culture | 無 | 無 | 無 |
| Dr. Leslie Tari Ph.D. | Chief Scientific Officer | 789.22k | 無 | 1967 |
描述
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
公司管治
截至 2024年6月1日 止，Cidara Therapeutics, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：10；董事會：7；股東權利：8；現金賠償：9。
